U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula Cu
Molecular Weight 63.546
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 2

SHOW SMILES / InChI
Structure of CUPRIC CATION

SMILES

[Cu++]

InChI

InChIKey=JPVYNHNXODAKFH-UHFFFAOYSA-N
InChI=1S/Cu/q+2

HIDE SMILES / InChI

Molecular Formula Cu
Molecular Weight 63.546
Charge 2
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Description
Sources: https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=a84d61a4-8e7f-4be1-aba6-f633b334aafc | http://www.sciencedirect.com/science/article/pii/S0167488912000158http://www.drugfuture.com/chemdata/schweizer-s-reagent.html | http://pubs.acs.org/doi/abs/10.1021/ed062p878?journalCode=jceda8 | http://pubs.acs.org/doi/abs/10.1021/ed019p356http://www.emdmillipore.com/US/en/product/Copper-di-ammonium-Titriplex-solution,MDA_CHEM-105217https://www.ncbi.nlm.nih.gov/pubmed/15704330 | https://www.ncbi.nlm.nih.gov/pubmed/12425037 | https://www.ncbi.nlm.nih.gov/pubmed/1599240 | http://www.certisusa.com/pdf-labels/Kocide3000_label.pdf | http://www.pesticideinfo.org/Detail_Chemical.jsp?Rec_Id=PC33524https://www.ncbi.nlm.nih.gov/pubmed/8556785 | https://www.ncbi.nlm.nih.gov/pubmed/2135524https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=522.518 | http://www.worldofchemicals.com/chemicals/chemical-properties/cupric-glycinate.htmlDOI: 10.1107/s0567740869001725 Retrived from http://scripts.iucr.org/cgi-bin/paper?S0567740869001725https://www.ncbi.nlm.nih.gov/pubmed/16971307https://www3.epa.gov/pesticides/chem_search/ppls/019713-00509-20110705.pdfhttp://www.drugfuture.com/chemdata/tetraamminecopper-sulfate.html | https://cameochemicals.noaa.gov/chemical/3026https://www.ncbi.nlm.nih.gov/pubmed/6526221http://fs1.agrian.com/pdfs/CORE_7.5_Copper_EDTA_Label.pdfhttps://www.ncbi.nlm.nih.gov/pubmed/24106015 | https://www.ncbi.nlm.nih.gov/pubmed/20942456http://www.ema.europa.eu/docs/en_GB/document_library/Maximum_Residue_Limits_-_Report/2009/11/WC500013010.pdf
Curator's Comment: description was created based on several sources, including https://www.copper.org/resources/properties/compounds/other_compounds.html | http://www.vitamins-supplements.org/dietary-minerals/copper.php | https://dailymed.nlm.nih.gov/dailymed/fda/fdaDrugXsl.cfm?setid=bea888b4-9cc6-49da-89e6-5c273b974ed1

Cupric oxide is the oxide of the copper with the chemical formula of CuO. It is used in the ceramic industry for imparting blue, green or red tints in glasses, glazes and enamels. Cupric oxide is also used as a source for copper in food supplements. Copper is an essential nutrient and a normal constituent of the diet in man and animals. The average daily dietary requirement for copper in humans has been estimated at 0.03 mg/kg body weight. Although rare, copper deficiency has been induced by supplemental zinc therapy.

CNS Activity

Curator's Comment: Known to be CNS active in zebrafish. Human data not available.

Originator

Sources: Schweizer, J. Prakt. Chem. 72, 109, 344 (1857).http://pubs.acs.org/doi/abs/10.1021/ja01512a012
Curator's Comment: http://www.drugfuture.com/chemdata/schweizer-s-reagent.html

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
3.42 µM [Ki]
Target ID: P00450
Gene ID: 1356.0
Gene Symbol: CP
Target Organism: Homo sapiens (Human)
Target ID: Glutathione S-transferase, rat, liver
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Preventing
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Preventing
Cupric glycinate

Approved Use

Indications for use. For beef calves and beef cattle for the prevention of copper deficiency, or when labeled for veterinary prescription use, for the prevention and/or treatment of copper deficiency alone or in association with molybdenum toxicity.
Primary
COPPER•MAX

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Preventing
Unknown

Approved Use

Unknown
Primary
Unknown

Approved Use

Unknown
Diagnostic
Unknown

Approved Use

Unknown
Preventing
COPPER

Approved Use

Copper 0.4 mg/mL (Cupric Chloride Injection, USP) is indicated for use as a supplement to intravenous solutions given for total parenteral nutrition (TPN). Administration helps to maintain copper serum levels and to prevent depletion of endogenous stores and subsequent deficiency symptoms.
Preventing
COPINOX

Approved Use

Copinox 4g is indicated for the prevention and treatment of copper deficiency in cattle and sheep.
PubMed

PubMed

TitleDatePubMed
A spectroscopic and thermoanalytical study of the mineral hoganite.
2007 May
Enhanced copper release from pipes by alternating stagnation and flow events.
2007 Nov 1
Synthesis and structural investigation of mono- and polynuclear copper complexes of 4-ethyl-1-(pyridin-2-yl) thiosemicarbazide.
2008 Nov 1
Zinc prevents the copper-induced damage of cultured astrocytes.
2010 Oct
Expeditious synthesis of phenanthrenes via CuBr2-catalyzed coupling of terminal alkynes and N-tosylhydrazones derived from o-formyl biphenyls.
2011 Oct 7
Evaluation of topically applied copper(II) oxide nanoparticle cytotoxicity in human skin organ culture.
2013 Feb
Cytotoxicity in the age of nano: the role of fourth period transition metal oxide nanoparticle physicochemical properties.
2013 Nov 25
Interference of CuO nanoparticles with metal homeostasis in hepatocytes under sub-toxic conditions.
2014
Unusual 4-arsonoanilinium cationic species in the hydrochloride salt of (4-aminophenyl)arsonic acid and formed in the reaction of the acid with copper(II) sulfate, copper(II) chloride and cadmium chloride.
2017 Apr 1
Ultrasonic energy enhanced the efficiency of advance extraction methodology for enrichment of trace level of copper in serum samples of patients having neurological disorders.
2017 Jul
Patents

Sample Use Guides

In Vivo Use Guide
Copper 0.4 mg/mL (Cupric Chloride Injection) contains 0.4 mg copper/mL and is administered intravenously only after dilution. The additive should be diluted in a volume of fluid not less than 100 mL. For the adult receiving total parenteral nutrition, the suggested additive dosage is 0.5 to 1.5 mg copper/day (1.25 to 3.75 mL/day). For pediatric patients, the suggested additive dosage is 20 mcg copper/kg/day (0.05 mL/kg/day). Infants weighing less than 1500 gm may have increased requirements because of their low body reserves and increased requirements for growth.
Route of Administration: Intravenous
Human Endometrial Stromal Cells were treated with non-toxic concentrations of copper ions (0-250 uM). mRNA expressions of insulin-like growth factor binding protein (IGFBP-1), prolactin (PRL), Mn-SOD, and FOXO1 were down-regulated during decidualization following the treatments with 100 or 250 uM copper ions. Meanwhile, the amount of malonaldehyde in the supernatant of cells was increased.
Substance Class Chemical
Created
by admin
on Fri Dec 16 17:11:29 UTC 2022
Edited
by admin
on Fri Dec 16 17:11:29 UTC 2022
Record UNII
8CBV67279L
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CUPRIC CATION
Common Name English
COPPER, ION (CU2+)
Common Name English
COPPER(II) ION
Common Name English
COPPER(II) CATION
Common Name English
CUPRIC ION
Common Name English
Classification Tree Code System Code
NCI_THESAURUS C68249
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
FDA ORPHAN DRUG 771520
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
Code System Code Type Description
CAS
15158-11-9
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
DAILYMED
8CBV67279L
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
RXCUI
1427198
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY RxNorm
EPA CompTox
DTXSID40934294
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
PUBCHEM
27099
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
CHEBI
29036
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
NCI_THESAURUS
C68251
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
FDA UNII
8CBV67279L
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
DRUG BANK
DB09130
Created by admin on Fri Dec 16 17:11:30 UTC 2022 , Edited by admin on Fri Dec 16 17:11:30 UTC 2022
PRIMARY
Related Record Type Details
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
LIGAND->TARGET
Scientific Literature
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
SALT/SOLVATE -> PARENT
Related Record Type Details
ACTIVE MOIETY